

Information for Provider on Antipsychotics during Pregnancy and Breastfeeding – January 2025

This chart is produced by the University of Illinois at Chicago (UIC) by Illinois DocAssist as a summary of research on antipsychotics in human pregnancy and breastfeeding

ANTIPSYCHOTIC RISKS IN PREGNANCY

Safety Data: No randomized control trials. Safety data derived largely from cohort studies, registry data, and prescription monitoring registries. Older studies suggested more adverse outcomes as they did not control for confounders such as presence and severity of maternal mental illness which is associated with adverse outcomes. Newer and better designed studies demonstrate less risks than previously believed. Because of antipsychotics' small molecular size, typically cross placenta at higher rates.¹³

Safety Ratings: Transition from Pregnancy Category (A, B, C, D, X) to PLLR (Pregnancy, Lactation, and Reproductive Labeling) as categories are confusing and did not accurately or consistently communicate differences in fetal risk. PLLR provides a risk summary based on available data in animal and human studies as well as clinical considerations for prescribers.

Obstetric Risks

- Both maternal illness and antipsychotics are associated with dose-dependent increased risk of preterm birth.^{9, 14, 21}
- Second generation antipsychotics are associated with higher risk of gestational DM, but more recent registry data found no increased risk of diabetes or gestational weight gain. Women taking antipsychotics were more likely to begin pregnancy with a higher BMI.^{6, 8, 9, 22}

Infant Risks

- **Congenital malformations**
 - New and well-designed studies show no associated increased risk for congenital malformations.^{7, 9, 19, 21}
- **Infant weight**
 - Some concern for increased infant weight related to metabolic risks of SGA, but registry data show mean birthweight of infants is within range of expected weight.^{5, 14, 21}
- **Adaptation**
 - Some evidence of a withdrawal/adjustment phenomenon with self-limited altered tone, difficulty breathing, or difficulty feeding^{9, 21}
 - Increased risk of neonatal EPS which may last up to 1 year (most resolve in 10 days¹), worse with higher D2-potency agents (haloperidol, chlorpromazine, risperidone.)¹⁹
- **Neurodevelopmental**
 - Neuromuscular delays at 6 months which resolve by 12 months.^{14, 21}
 - No difference in behavior, development, nor IQ at 5 years old.¹

**If you have questions or need a consultation, contact Illinois DocAssist
at 866-986-2778 to speak with a psychiatric consultant.**

Information for Provider on Antipsychotics during Pregnancy and Breastfeeding – January 2025

This chart is produced by the University of Illinois at Chicago (UIC) by Illinois DocAssist as a summary of research on antipsychotics in human pregnancy and breastfeeding

ANTIPSYCHOTIC RISKS IN BREASTFEEDING

Safety data: Includes limited studies examining relative infant dose, medication concentration in breastmilk, and infant plasma concentration as well as reports of adverse events.

Risks:

- Poor feeding, lethargy, irritability, not waking to feed, jitteriness, poor weight gain.
- Infants are exposed to much higher doses in-utero, therefore women should not be counseled to discontinue medications or not breastfeed due to low comparative exposure from breast milk.
- Theoretical risk to milk production based on prolactin disturbance by antipsychotics, but inconsistent data and not a reason to avoid breast feeding ⁶

Safety rating:

Dr. Hale's Lactation Risk Categories L1-L5

L1 SAFEST – Drug has been taken by many breastfeeding women without evidence of adverse effects in nursing infants OR controlled studies have failed to show evidence of risk.

L2 SAFER – Drug has been studied in a limited number of breastfeeding women without evidence of adverse effects in nursing infants.

L3 MODERATELY SAFE – Studies in breastfeeding have shown evidence for mild non-threatening adverse effects OR there are no studies in breastfeeding for a drug with possible adverse effects.

L4 POSSIBLY HAZARDOUS – Studies have shown evidence for risk to a nursing infant, but in some circumstances the drug may be used during breastfeeding.

L5 CONTRAINDICATED – Studies have shown significant risk to nursing infants. The drug should NOT be used during breastfeeding.

Clinical Considerations

- No medication is risk free.
- The risks of psychotropic use in pregnancy and lactation must be weighed with the risks of untreated or undertreated psychiatric illness to the mother and child.
- In psychotropic naive women, quetiapine is the drug of choice in pregnancy and breastfeeding.
- If a patient is pregnant and stable on a non-first line medication, the risk of changing medications (relapse of symptoms, multiple drug exposures in pregnancy) may outweigh the benefits for the mother-infant dyad.
- Untreated or undertreated psychosis is associated with preterm labor, decreased obstetric and medication adherence, increased rates of substance use (especially tobacco), suicide, impaired bonding and attachment with infant, postpartum mood or psychotic episodes, and risk of mental disorders in infant.
- Treatment target is remission of symptoms.
- Drug metabolism in pregnancy may change due to alterations in enzymatic activity such as CYP 2D6 and 3A4 and increased creatinine clearance. May consider supra-therapeutic doses in the context.



Call for questions or
a consultation

866-986-2778

Information for Provider on Antipsychotics during Pregnancy and Breastfeeding – January 2025

This chart is produced by the University of Illinois at Chicago (UIC) by Illinois DocAssist as a summary of research on antipsychotics in human pregnancy and breastfeeding

	Medication	Advantages	Disadvantages	Relative Infant Dose	Lactation Rating*	Potential adverse effects of breastfeeding
First Generation Antipsychotic	Haloperidol	<ul style="list-style-type: none"> • Long-acting injectable • More data compared to SGA 	<ul style="list-style-type: none"> • Risk of infant EPS • Concomitant use of anticholinergics to manage side effects have increased risk of teratogenicity¹⁹ 	0.2-12%	L3	<ul style="list-style-type: none"> • Sedation
	Chlorpromazine	<ul style="list-style-type: none"> • Data supporting treatment of pregnancy-induced nausea/vomiting¹⁸ • More data compared to SGA 	<ul style="list-style-type: none"> • Risk of infant EPS • Concomitant use of anticholinergics to manage side effects have increased risk of teratogenicity¹⁹ • Increased metabolic side effects 	0.3%	L3	<ul style="list-style-type: none"> • Sedation
Second Generation Antipsychotic	Quetiapine	<ul style="list-style-type: none"> • Lower placental passage and breastmilk compared to other antipsychotics²⁰ 	<ul style="list-style-type: none"> • No IM formulation • Increased metabolic side effects 	0.02-0.1%	L2	<ul style="list-style-type: none"> • Drowsiness, weight gain, delayed milestones²¹
	Risperidone	<ul style="list-style-type: none"> • Long-acting injectable 	<ul style="list-style-type: none"> • Increased metabolic side effects • Risk of infant EPS • Possible statistically significant RR of 1.26 for any major malformation⁶ 	2.8-9.1%	L2	<ul style="list-style-type: none"> • Sedation
	Olanzapine		<ul style="list-style-type: none"> • Highest rate of placental transfer¹⁹ • Greatest increased risk of metabolic side effects¹⁹ 	0.28-2.24%	L2	<ul style="list-style-type: none"> • Sedation
	Paliperidone	<ul style="list-style-type: none"> • Long-acting injectable 	<ul style="list-style-type: none"> • Increased metabolic side effects • Less data than other agents 	ND	L3	
	Aripiprazole	<ul style="list-style-type: none"> • Long-acting injectable • Less risk of metabolic side effects² 		0.7-6.44%	L3	
	Ziprasidone	<ul style="list-style-type: none"> • Less risk of metabolic side effects 	<ul style="list-style-type: none"> • Less data than other agents 	0.07-1.2%	L2	
	Lurasidone	<ul style="list-style-type: none"> • Less risk of metabolic side effects 	<ul style="list-style-type: none"> • Less data than other agents 	ND	L3	
	Clozapine	<ul style="list-style-type: none"> • Best in treatment refractory women 	<ul style="list-style-type: none"> • Frequent lab monitoring • Increased metabolic side effects 	1.33-1.4%	L3	<ul style="list-style-type: none"> • High secretion into breast milk • Theoretical risk for neonatal agranulocytosis or seizure (though no reported cases)¹⁹

L1 SAFEST – Drug has been taken by many breastfeeding women without evidence of adverse effects in nursing infants OR controlled studies have failed to show evidence of risk.

L2 SAFER – Drug has been studied in a limited number of breastfeeding women without evidence of adverse effects in nursing infants.

L3 MODERATELY SAFE – Studies in breastfeeding have shown evidence for mild non-threatening adverse effects OR there are no studies in breastfeeding for a drug with possible adverse effects.

L4 POSSIBLY HAZARDOUS – Studies have shown evidence for risk to a nursing infant, but in some circumstances the drug may be used during breastfeeding.

L5 CONTRAINDICATED – Studies have shown significant risk to nursing infants. The drug should NOT be used during breastfeeding.

© 2025 The Board of Trustees of the University of Illinois. All rights reserved



866-986-2778

Information for Provider on Antipsychotics during Pregnancy and Breastfeeding – January 2025

This chart is produced by the University of Illinois at Chicago (UIC) by Illinois DocAssist as a summary of research on antipsychotics in human pregnancy and breastfeeding

1. Babu GN, Desai G, Chandra PS. Antipsychotics in pregnancy and lactation. *Indian J Psychiatry*. 2015;57(Suppl 2):303. Accessed May 20, 2019. doi: 10.4103/0019-5545.161497.
2. Bellet F, Beyens M, Bernard N, Beghin D, Elefant E, Vial T. Exposure to aripiprazole during embryogenesis: A prospective multicenter cohort study. *Pharmacoepidemiol Drug Saf*. 2015;24(4):368-380. Accessed May 20, 2019. doi: 10.1002/pds.3749.
3. Bergink V, Rasgon N, Wisner KL. Postpartum psychosis: Madness, mania, and melancholia in motherhood. *Am J Psychiatry*. 2016;173(12):1179-1188. Accessed May 20, 2019. doi: 10.1176/appi.ajp.2016.16040454.
4. Cohen LS, Viguera AC, McInerney KA, et al. Reproductive safety of second-generation antipsychotics: Current data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics. *Am J Psychiatry*. 2016;173(3):263-270. Accessed May 20, 2019. doi: 10.1176/appi.ajp.2015.15040506.
5. Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy. *Obstet Gynecol*. 2015;125(5):1224-1235. Accessed May 20, 2019. doi: 10.1097/AOG.0000000000000759.
6. Cuomo A, Goracci A, Fagiolini A. Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice. *J Affect Disord*. 2018;228:229-237. Accessed May 20, 2019. doi: 10.1016/j.jad.2017.12.021.
7. Ennis ZN, Damkier P. Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review. *Basic Clin Pharmacol Toxicol*. 2015;116(4):315-320. Accessed May 20, 2019. doi: 10.1111/bcpt.12372.
8. Freeman MP, Sosinsky AZ, Goez-Mogollon L, Savella GM, Moustafa D, Viguera AC, Cohen LS. Gestational Weight Gain and Pre-pregnancy Body Mass Index Associated With Second-Generation Antipsychotic Drug Use During Pregnancy. *Psychosomatics*. 2017 Sep 21.
9. Galbally M, Snellen M, Power J. Antipsychotic drugs in pregnancy: A review of their maternal and fetal effects. *Ther Adv Drug Saf*. 2014;5(2):100-109. Accessed May 20, 2019. doi: 10.1177/2042098614522682.
10. Gentile S. Pregnancy exposure to second-generation antipsychotics and the risk of gestational diabetes. *Expert Opin Drug Saf*. 2014;13(12):1583-1590. Accessed May 20, 2019. doi: 10.1517/14740338.2014.931368.
11. Gentile S. A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium. *Expert Opin Drug Saf*. 2014;13(12):1733-1742. Accessed May 20, 2019. doi: 10.1517/14740338.2014.951325.
12. Habermann F, Fritzsche J, Fuhlbrück F, et al. Atypical antipsychotic drugs and pregnancy outcome: A prospective, cohort study. *J Clin Psychopharmacol*. 2013;33(4):453-462. Accessed May 20, 2019. doi: 10.1097/JCP.0b013e318295fe12.

Information for Provider on Antipsychotics during Pregnancy and Breastfeeding – January 2025

This chart is produced by the University of Illinois at Chicago (UIC) by Illinois DocAssist as a summary of research on antipsychotics in human pregnancy and breastfeeding

13. Kimmel MC, Cox E, Schiller C, Gettes E, Meltzer-Brody S. Pharmacologic treatment of perinatal depression. *Obstet Gynecol Clin North Am.* 2018;45(3):419-440. Accessed May 20, 2019. doi: 10.1016/j.ogc.2018.04.007.
14. Kulkarni J, Storch A, Baraniuk A, Gilbert H, Gavrilidis E, Worsley R. Antipsychotic use in pregnancy. *Expert Opin Pharmacother.* 2015;16(9):1335-1345. Accessed May 20, 2019. doi: 10.1517/14656566.2015.1041501.
15. Nulman I. The effects of the new antipsychotic medications on mothers and babies. *J Popul Ther Clin Pharmacol.* 2014;21(3):542. Accessed May 20, 2019.
16. Ornoy A, Weinstein-Fudim L, Ergaz Z. Antidepressants, antipsychotics, and mood stabilizers in pregnancy: What do we know and how should we treat pregnant women with depression. *Birth Defects Res.* 2017;109(12):933-956. Accessed May 20, 2019. doi: 10.1002/bdr2.1079.
17. Poo SXW, Agius M. Atypical antipsychotics for schizophrenia and/or bipolar disorder in pregnancy: Current recommendations and updates in the NICE guidelines. *Psychiatr Danub.* 2015;27 Suppl 1:255. Accessed May 20, 2019.
18. Rodriguez-Cabezas L, Clark C. Psychiatric emergencies in pregnancy and postpartum. *Clin Obstet Gynecol.* 2018;61(3):615-627. Accessed May 20, 2019. doi: 10.1097/GRF.0000000000000377.
19. Smith B, Dubovsky SL. Pharmacotherapy of mood disorders and psychosis in pre- and post-natal women. *Expert Opin Pharmacother.* 2017;18(16):1703-1719. Accessed May 20, 2019. doi: 10.1080/14656566.2017.1391789.
20. Terrana N, Koren G, Pivovarov J, Etwel F, Nulman I. Pregnancy outcomes following in utero exposure to second-generation antipsychotics: A systematic review and meta-analysis. *J Clin Psychopharmacol.* 2015;35(5):559-565. Accessed May 20, 2019. doi: 10.1097/JCP.0000000000000391.
21. Thorsness KR, Watson C, LaRusso EM. Perinatal anxiety: Approach to diagnosis and management in the obstetric setting. *Am J Obstet Gynecol.* 2018;219(4):326-345. Accessed May 20, 2019. doi: 10.1016/j.ajog.2018.05.017.
22. Wesseloo R, Kamperman AM, Munk-Olsen T, Pop VJM, Kushner SA, Bergink V. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: A systematic review and meta-analysis. *Am J Psychiatry.* 2016;173(2):117-127. Accessed May 20, 2019. doi: 10.1176/appi.ajp.2015.15010124.
23. Whitworth AB. Psychopharmacological treatment of schizophrenia during pregnancy and lactation. *Curr Opin Psychiatry.* 2017;30(3):184-190. Accessed May 20, 2019. doi: 10.1097/YCO.0000000000000329.